Wearable UV patch keeps skin safe in the summer

Cara Livernois | | Health Exec | Precision Medicine

Summer is the season to be spending time in the sun, but too many rays can lead to skin cancer. A new wearable patch aims to help wearers beat the heat by notifying them in cases of over exposure.

My UV Patch is paired with a smartphone app to evaluate a user's time in the sun. The patch is able to alert wearers of overexposure by changing color when in contact with ultraviolet rays, send messages reminding wearer to reapply sunscreen or supply sun safety tips based on results from the patch.

"The wearables have the potential to engage someone like a teenager or a child to where they can understand that there's a link between how much sunscreen they put on, how much time they stay outside and the sun exposure they get," said dermatologist Gene Rubinstein, MD.

High-tech wearable UV patch aims to improve sun safety

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup